Jump to main content
Jump to site search

Issue 6, 2013
Previous Article Next Article

Glucose conjugation for the specific targeting and treatment of cancer

Author affiliations

Abstract

Cancers of diverse origins exhibit marked glucose avidity and high rates of aerobic glycolysis. Increased understanding of this dysfunctional metabolism known as the Warburg effect has led to an interest in targeting it for cancer therapy. One promising strategy for such targeting is glycoconjugation, the linking of a drug to glucose or another sugar. This review summarizes the most salient examples of glycoconjugates, in which known cytotoxins or anticancer therapeutics have been linked to glucose (or another glucose transporter substrate sugar) for improved cancer targeting and selectivity. Building on these examples, this review also provides a series of guidelines for the design and mechanistic evaluation of future glycoconjugates.

Graphical abstract: Glucose conjugation for the specific targeting and treatment of cancer

Back to tab navigation

Publication details

The article was received on 11 Dec 2012, accepted on 08 Apr 2013 and first published on 08 Apr 2013


Article type: Minireview
DOI: 10.1039/C3SC22205E
Citation: Chem. Sci., 2013,4, 2319-2333
  •   Request permissions

    Glucose conjugation for the specific targeting and treatment of cancer

    E. C. Calvaresi and P. J. Hergenrother, Chem. Sci., 2013, 4, 2319
    DOI: 10.1039/C3SC22205E

Search articles by author

Spotlight

Advertisements